Bremelanotide: First Approval.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing drug development and regulatory milestones without primary empirical data or systematic review methodology.
PubMed 31429064 · doi:10.1007/s40265-019-01187-w
What was done
This review summarized the developmental milestones, mechanism of action, and regulatory pathway leading to the US FDA approval of bremelanotide (Vyleesi) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
What was found
The abstract reports no quantitative clinical trial results or numerical findings. It describes bremelanotide as a self-administered, on-demand subcutaneous synthetic peptide analogue of alpha-melanocyte-stimulating hormone with high affinity for melanocortin type 4 receptors.
Why it matters
It documents the first regulatory approval of a targeted melanocortin receptor agonist for premenopausal women experiencing distress or interpersonal difficulty from low sexual desire.
Limits
The abstract provides narrative developmental history without quantitative efficacy metrics, safety data, sample sizes, comparator details, or long-term clinical outcomes.
Cited by
- supports Bremelanotide (PT-141) is a derivative of Melanotan II available as a prescription medication that provides sexual function benefits without skin tanning.